Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275095 | 0.85 | CYP2C9 (0.38) | CYP2C9KDM4ELMNAPKMKMT2A | |
| SCHEMBL1274490 | 0.82 | POLB (0.38) | CYP2C9ALDH1A1POLBTSHRSLC16A3 | |
| SCHEMBL4364409 | 0.81 | CYP2C9 (0.62) | CYP2C9KDM4ELMNAPKMKMT2A | |
| SCHEMBL30580 | 0.81 | CYP2C9 (0.38) | CYP2C9KDM4ELMNAPKMKMT2A | |
| SCHEMBL8291138 | 0.81 | CYP2C9 (0.62) | CYP2C9KDM4ELMNAPKMKMT2A | |
| SCHEMBL13750059 | 0.81 | CYP2C9 (0.45) | CYP2C9KDM4ELMNAPKMKMT2A | |
| SCHEMBL4364407 | 0.81 | CYP2C9 (0.62) | CYP2C9KDM4ELMNAPKMKMT2A | |
| SCHEMBL5554902 | 0.80 | ALDH1A1 (0.40) | CYP2C9KDM4ELMNAPKMKMT2A | |
| SCHEMBL15309080 | 0.80 | KDM4E (0.40) | CYP2C9KDM4ELMNAPKMKMT2A | |
| SCHEMBL28676504 | 0.79 | ALDH1A1 (0.36) | CYP2C9KDM4ELMNAPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971421-B1 | INSERTION-POINT SEAL FOR SPIRAL WOUND MODULE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-07-06 | — | — | EP | claimed |
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-111278938-B | Toughened low odor/low bloom cyanoacrylate compositions | 汉高股份有限及两合公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-111263778-B | Cyanoacrylate compositions | 汉高股份有限及两合公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-111278878-B | Cyanoacrylate compositions | 汉高股份有限及两合公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20210093613-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3700991-A1 | TOUGHENED, LOW ODOR/LOW BLOOM CYANOACRYLATE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2020-09-02 | — | — | EP | disclosed |
| EP-3700951-A1 | CYANOACRYLATE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2020-09-02 | — | — | EP | disclosed |
| EP-3700950-A1 | CYANOACRYLATE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2020-09-02 | — | — | EP | disclosed |
| US-10744118-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| CN-111263778-A | Cyanoacrylate compositions | 汉高知识产权控股有限责任公司 | 2020-06-09 | — | — | CN | disclosed |
| EP-2928474-B1 | DIAZOLE LACTAMS | CHEMOCENTRYX INC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20160303084-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2928474-A1 | DIAZOLE LACTAMS | ChemoCentryx, Inc. (US) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014089495-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| EP-0971588-B1 | NOVEL CANNABINOID RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-0971588-A4 | NOVEL CANNABINOID RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6100259-A | 1-(DISUBSTITUTED PHENYL)4,5-SUBSTITUTED PYRAZOLE DERIVATIVES OF GIVEN FORMULA; ANTAGONIZING CANNABINOID 2 RECEPTORS; TREATING RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, PSORIASIS, MULTIPLE SCLEROSIS, DIABETES AND THYROIDITIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0971588-A1 | NOVEL CANNABINOID RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998031227-A1 | NOVEL CANNABINOID RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303084-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | CYP2C9 3044/4885KDM4E 3801/4885LMNA 3948/4885 |
| US-20210093613-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | CYP2C9 3044/4885KDM4E 3801/4885LMNA 3948/4885 |
| US-10744118-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | CYP2C9 3044/4885KDM4E 3801/4885LMNA 3948/4885 |
| US-11759454-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | CYP2C9 3044/4885KDM4E 3801/4885LMNA 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.